ニュース
2 時間on MSN
The FDA Just Approved a New Use for Wegovy, and Novo Nordisk Stock is Climbing. Here's What ...
Wegovy is now the second medicine approved in the U.S. for a disease that affects millions. Novo Nordisk has several other ...
Patients' vision loss, which is rare according to a new study, is also the subject of multiple lawsuits, including two filed ...
Discover potential risks for Novo Nordisk using Charlie Munger's inversion model. Explore market share, R&D, and why this ...
GoodRx and Novo Nordisk are partnering to lower costs for Ozempic and Wegovy. Patients can use GoodRx to access ...
As Novo Nordisk transitions from the leadership of longtime CEO Lars Fruergaard Jørgensen to newly appointed chief Maziar ...
(CNN)– Patients in the U.S. can now get Ozempic for half the price, if they pay in cash. Novo Nordisk, the maker of the diabetes drug announced Monday, Aug. 19, that U.S. patients can now get a ...
Novo Nordisk and GoodRx announced a partnership this week to sell products Ozempic and Wegovy at half their normal cost to ...
Novo Nordisk lowers Ozempic cost to $499 per month for uninsured U.S. patients, expanding access through NovoCare and 70,000 ...
After Novo Nordisk revealed Ozempic will retail for half-price at 70,000 pharmacies throughout the US, people are questioning ...
Health Canada approved Ozempic for type 2 diabetes patients with chronic kidney disease after positive FLOW trial results.
Novo Nordisk is slashing the price of its blockbuster diabetes drug Ozempic for U.S. patients who self-pay or are uninsured.
As China rises and other global cities aggressively court biotech talent, Massachusetts faces a "contracting moment" that has ...
一部の結果でアクセス不可の可能性があるため、非表示になっています。
アクセス不可の結果を表示する